US EditionFactbox-Launches of Novo Nordisk’s weight-loss drug Wegovy
- Novo Nordisk has launched its weight-loss drug, Wegovy, in the U.K., despite ongoing supply constraints. The weekly injection will be available initially through a controlled and limited launch, with certain patients eligible to receive the drug on the country's National Health Service . To qualify for treatment, patients must be on the NHS's weight management service, have at least one weight-related condition, and have a body mass index of 35.
- The final price for Wegovy agreed with NHS England is undisclosed, but it has been described as a "cost-effective use of NHS resources" by the U.K. drug cost-effectiveness watchdog. In the U.S., Wegovy has a list price of $1,350 for a monthly dose, while in Europe it retails for around 170 to 300 euros per month.
- Novo Nordisk will prioritize patients with the highest unmet medical need and work with healthcare professionals to ensure access to Wegovy. However, supply constraints continue to impact the drug's rollout, and the company expects it will take "some years" to satisfy all consumers' demand.
5 Articles
5 Articles
Weight-loss drug Wegovy launches in the UK as Novo Nordisk shares reach new heights amid supply challenges
The Danish pharmaceutical company Novo Nordisk has introduced its weight-loss drug Wegovy to the United Kingdom. This strategic expansion into new markets comes in the face of persistent supply shortages, which the company expects to endure for several years due to surging demand.
Factbox-Launches of Novo Nordisk’s weight-loss drug Wegovy
(Reuters) - Novo Nordisk is pushing ahead with the launches of weight-loss drug Wegovy in Europe even as it struggles to keep up with demand. The Danish drugmaker is working to convince European governments and insurers to reimburse the drug, seeking to position it as more than a lifestyle drug. Below are the countries where Wegovy has been launched so far: U.S. Wegovy was launched in the U.S. in June 2021 but it took Novo until December 202…
The company Novo Nordisk is trying to expand in Europe, although it faces difficulties in responding to the increase in demand for this drug.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
